Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy
AuthorsPelly, Victoria S
Roelofsen, L. M.
Bell, Charlotte R
Bromley, Christian P
Schumacher, T. N.
AffiliationCancer Inflammation and Immunity, CRUK Manchester Institute.
MetadataShow full item record
AbstractIdentifying strategies to improve the efficacy of immune checkpoint blockade (ICB) remains a major clinical need. Here, we show that therapeutically targeting the COX-2/PGE2/EP2-4 pathway with widely used non-steroidal and steroidal anti-inflammatory drugs synergized with ICB in mouse cancer models. We exploited a bilateral surgery model to distinguish responders from non-responders shortly following treatment and identified acute IFN-γ-driven transcriptional remodeling in responder mice, which was also associated with patient benefit to ICB. Monotherapy with COX-2 inhibitors or EP2-4 PGE2 receptor antagonists rapidly induced this response program and, in combination with ICB, increased the intratumoral accumulation of effector T cells. Treatment of patient-derived tumor fragments from multiple cancer types revealed a similar shift in the tumor inflammatory environment to favor T cell activation. Our findings establish the COX-2/PGE2/EP2-4 axis as an independent immune checkpoint and a readily translatable strategy to rapidly switch the tumor inflammatory profile from cold to hot.
CitationPelly VS, Moeini A, Roelofsen LM, Bonavita E, Bell CR, Hutton C, et al. Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy. Cancer Discov. 2021 May 24;candisc.1815.2020.
- Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
- Authors: Kwong TT, Wong CH, Zhou JY, Cheng ASL, Sung JJY, Chan AWH, Chan SL
- Issue date: 2021 Apr
- A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade.
- Authors: Chen IX, Newcomer K, Pauken KE, Juneja VR, Naxerova K, Wu MW, Pinter M, Sen DR, Singer M, Sharpe AH, Jain RK
- Issue date: 2020 Sep 22
- CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.
- Authors: Wang G, Chow RD, Zhu L, Bai Z, Ye L, Zhang F, Renauer PA, Dong MB, Dai X, Zhang X, Du Y, Cheng Y, Niu L, Chu Z, Kim K, Liao C, Clark P, Errami Y, Chen S
- Issue date: 2020 Dec
- Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
- Authors: Han X, Li H, Zhou D, Chen Z, Gu Z
- Issue date: 2020 Nov 17
- Regulation of immune checkpoint blockade efficacy in breast cancer by FIP200: A canonical-autophagy-independent function.
- Authors: Yeo SK, Guan JL
- Issue date: 2020 Jul 2